Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

CCHR Files Over 6,000 Complaints About Mental Health Abuse and Psychiatric-Pharma Violations of Human Rights


News provided by

Citizens Commission on Human Rights International

Sep 19, 2017, 10:00 ET

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, Sept. 19, 2017 /PRNewswire/ -- Citizens Commission on Human Rights International (CCHR), a 48-year mental health watchdog headquartered in Los Angeles, is calling for anyone who has a family member or friend abused in the mental health system to contact the group for assistance. In the last year, CCHR filed more than 6,000 complaints to state and federal health and mental health agencies, departments of justice, FBI and legislators on behalf of individuals whose rights, lives and insurance coverage were potentially endangered undergoing psychiatric treatment. Of these, over 4,000 involved the for-profit behavioral system that is estimated to be a $50 billion a year industry. Of this, the inpatient behavioral market, which largely provides psychopharmaceuticals and electroshock as its mainstay treatments, is worth around $20 billion."[1]  

Continue Reading
CCHR Files Over 6,000 Complaints About Mental Health Abuse and Psychiatric-Pharma Violations of Human Rights
CCHR Files Over 6,000 Complaints About Mental Health Abuse and Psychiatric-Pharma Violations of Human Rights

CCHR operates a hotline and an online abuse report form for those needing assistance for a loved one that may be unable to speak up due to the damage they have experienced as a result of treatment in the mental health system. CCHR also receives scores of calls from those working in the industry providing information, especially courageous nurses that want to report their concerns about potential negligence, sexual and physical assaults on patients, dangerous prescription practices and over-billing. Nearly 60 percent of all mental health spending is from public funding sources in the U.S.[2] and nurses report seeing that expenditure being wasted or abused.

Those contacting CCHR for information can also be assisted with educational materials on their rights under the law, such as the Federal Prohibition of Child Medication Safety Act. A video of five mothers whose information from CCHR helped protect or save their children's lives has been an inspiration to many. As one mother named Cindy said of CCHR, "Having so many people that I could reach out to, and give me advice to deal with the situation made a humongous change in his education.... It pretty much saved my child's life."

Jeri, another mother says, "I went to the internet and Googled, 'do I have rights not to drug my child' and CCHR popped up.... They told me I don't have to drug my child because it's against federal law.... I didn't know about the federal law until I spoke with CCHR and I was going to be able to keep my son without drugging him. That was probably the best day of my life."

And Lenore, the mother of a three-year-old prescribed stimulants and antidepressants with serious adverse effects adds, "CCHR is definitely not trying to make anybody feel like they did anything wrong for their children or their family. They're here to support you, they're here to help you seek out the correct information and weed through what is fact and what isn't fact." With medical assistance, her child is no longer on mind-altering psychotropic drugs. "Being off the medication has changed my son's life—it's changed my life...," Lenore says.

"CCHR works to ensure patient and consumer protections are enacted and upheld because there is rampant abuse in the field of mental health. One of the first protections an individual or parents can have is to be informed and CCHR helps people easily access information," says Jan Eastgate, President of CCHR International.

The group extensively researches current trends in mental health and remains concerned about the risks of psychotropic drugs, offering a psychiatric drugs side effects database online with which people can inform themselves. It also provides facts about electroshock. CCHR says it does so because many patients and their families are not fully informed about side effects.

"Psychopharmacological interventions are accounting for a larger proportion of all psychiatric care," according to a study published in The Psychiatric Bulletin. Between 1996 and 2008 alone, the increase in antipsychotics went from 9.3 million to 23.0 million.[3] In 2015, Medicaid spent $2 billion on one antipsychotic alone.[4] "The high rates of psychotropic medication use in the Medicaid population, risks associated with these drugs, and research documenting inappropriate prescribing, have raised concerns, especially for children involved in the child welfare system and older adults with dementia," a 2015 government report, "Use of Psychotropic Medications Among Medicaid Beneficiaries" found.[5]

CCHR says that with prominent warnings now about psychotropic drug risks, the country shouldn't be witnessing the high numbers of Americans, especially children, being prescribed these drugs that expose them to potential long-term damage. For example, it points to the Food and Drug Administration (FDA) recently approving a new drug, valbenazine, to counter the iatrogenic (doctor/treatment caused) effects of antipsychotics—a movement disorder called tardive dyskinesia (TD). The symptoms of TD include lip smacking or pursing, chewing, facial grimacing, and tongue movements inside the mouth or tongue popping out. It is prevalent in an estimated 20–50 percent of all patients treated with neuroleptics (antipsychotics).[6]

Yet valbenazine can cause gait disturbance, trouble with balance and coordination and fatigue[7]—symptoms similar to those seen caused by antipsychotics. It's a win-win for the psychiatric-pharmaceutical industry, CCHR says, but not for the victims of it. Antipsychotics (and other psychopharmaceuticals) cause TD. Psychiatrists then redefine this prescription drug damage as another mental disorder: "neuroleptic-induced disorders," "medication-induced movement disorders" or "neuroleptic malignant disorder." These are inserted in the Diagnostic and Statistical Manual of Mental Disorders (DSM) with a billing code to obtain insurance reimbursement for their treatment. Based on IMS information, there were at least 6.84 million Americans taking antipsychotics in 2013.[8] That means between 1.37 and 3.4 million people could be suffering TD caused by the very treatment prescribed to "help" them. Valbenazine costs around $64,000 a year, according to Market Watch.[9]

Hypothetically, were each of those prescribed this latest drug, the manufacturer could benefit between $87.6 billion and $217 billion.

Victims of psychiatric abuse, as well as their friends and family, are encouraged to call CCHR's hotline at 1-800-869-2247 or fill out an abuse case report form on the CCHR website. 

As a nonprofit, CCHR relies on memberships and donations to carry out its mission and actions to research and provide information so that individuals are better educated about their rights. It has already been responsible for helping get over 180 laws enacted that help protect rights within the mental health system. Click here to support the cause.

Contact: Amber Rauscher, [email protected] or (323) 467-4242.

References:

[1] http://marketrealist.com/2015/01/assessing-universal-health-services-revenue-mix-admissions/; http://marketrealist.com/2015/01/exploring-universal-health-services-major-markets

[2] L. Mark Russakoff, "Private in-patient psychiatry in the USA," The Psychiatric Bulletin, Oct. 2014, 38(5): 230–235, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180988

[3] L. Mark Russakoff, "Private in-patient psychiatry in the USA," The Psychiatric Bulletin, Oct. 2014, 38(5): 230–235, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180988/

[4] https://www.advisory.com/daily-briefing/2016/11/16/what-medicare-and-medicaid-spent-on-drugs-2015

[5] Medicaid and CHIP Payment and Access Commission (MACPAC), https://www.macpac.gov/wp-content/uploads/2015/06/Use-of-Psychotropic-Medications-among-Medicaid-Beneficiaries.pdf

[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709416

[7] http://www.rxlist.com/ingrezza-side-effects-drug-center.htm

[8] https://www.cchrint.org/psychiatric-drugs/people-taking-psychiatric-drugs

[9] http://www.marketwatch.com/story/neurocrine-biosciences-new-drug-may-cost-patients-taking-recommended-dose-twice-as-much-as-expected-2017-04-26

SOURCE Citizens Commission on Human Rights International

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.